Key clinical point: A single infusion of zoledronic acid does not completely prevent bone mineral density loss regardless of the timing of the infusion in patients with osteopenia who discontinued denosumab (Prolia).
Major finding: The average bone loss was 4.6% at the lumbar spine and 3.2% for total hip with no clinically significant between-group differences for either site.
Study details: A 2-year, randomized, open-label study of 60 patients who were administered zoledronic acid at 6 months or 9 months after the last dose of denosumab or after increased bone turnover.
Disclosures: This study was funded in part by Amgen, the Foundation of Vilhelm Pedersen and wife, Aarhus University, the Danish Osteoporosis Society Research Foundation, the P. Carl Petersens Foundation, and the Torkil Steenbeck Foundation. The presenter reported receiving research funding from Amgen and Novo Nordisk and is on the advisory board for Amgen, Eli Lilly, and UCB.
Sølling A. ASBMR 2019, Abstract LB-1169